Our findings also suggest that p53 wild-type NSCLC cells that exhibit elevated expression levels of CSE1L and AURKA pathway genes may be particularly responsive to the HDAC1/2 inhibitor mocetinostat. The gene discussed is TP53; the disease is non-small cell lung carcinoma.